Drug Profile
Research programme: SPAN-X cancer therapy - University of Virginia
Alternative Names: Research programme: SPAN-X tumour therapy; SPAN-X cancer therapy research programmeLatest Information Update: 20 Jan 2003
Price :
$50
*
At a glance
- Originator University of Virginia
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Jan 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 14 Feb 2001 Preclinical development for Cancer in USA (Unknown route)